Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | RARB | P10826 | 5/20 | 0.41 |
| ▸ | RARA | P10276 | 5/20 | 0.41 |
| ▸ | RARG | P13631 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL548533 | 0.87 | MEN1 (0.50) | MEN1KMT2AGAAPOLBGFER | |
| SCHEMBL4677956 | 0.86 | MEN1 (0.53) | MEN1KMT2AGAAPOLBGFER | |
| SCHEMBL549697 | 0.85 | MEN1 (0.49) | MEN1KMT2AGAAPOLBGFER | |
| SCHEMBL3768061 | 0.85 | MEN1 (0.52) | MEN1KMT2AGAAPOLBGFER | |
| SCHEMBL548756 | 0.82 | MEN1 (0.46) | MEN1KMT2AGAAPOLBGFER | |
| SCHEMBL549467 | 0.82 | MEN1 (0.39) | MEN1KMT2AGAAPOLBGFER | |
| SCHEMBL27419051 | 0.80 | MEN1 (0.47) | MEN1KMT2AGAAPOLBGFER | |
| SCHEMBL27199192 | 0.80 | MEN1 (0.47) | MEN1KMT2AGAAPOLBGFER | |
| SCHEMBL548996 | 0.80 | MEN1 (0.48) | MEN1KMT2AGAAPOLBGFER | |
| SCHEMBL548653 | 0.80 | MEN1 (0.59) | MEN1KMT2AGAAPOLBGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124501-A1 | VANADIUM COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION | 2024-04-18 | — | — | US | disclosed |
| US-8110614-B2 | Adamantane derivative, method for producing the same, and resin composition containing adamantane derivative | IDEMITSU KOSAN CO., LTD. (JP) | 2012-02-07 | — | — | US | disclosed |
| US-20100056663-A1 | ADAMANTANE DERIVATIVE, METHOD FOR PRODUCING THE SAME, AND RESIN COMPOSITION CONTAINING ADAMANTANE DERIVATIVE | IDEMITSU KOSAN CO., LTD. (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2090563-A1 | ADAMANTANE DERIVATIVE, METHOD FOR PRODUCING THE SAME, AND RESIN COMPOSITION CONTAINING ADAMANTANE DERIVATIVE | IDEMITSU KOSAN COMPANY LIMITED (JP) | 2009-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124501-A1 | VANADIUM COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | ATP6V1B2, MVD, VDAC3 | MEN1 510/4885KMT2A 1389/4885GAA 868/4885 |
| US-20100056663-A1 | ADAMANTANE DERIVATIVE, METHOD FOR PRODUCING THE SAME, AND RESIN COMPOSITION CONTAINING ADAMANTANE DERIVATIVE | ARCN1, RTN3, CHRNA3 | MEN1 3412/4885KMT2A 3737/4885GAA 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.